Suven Life Sciences secures 3 Product Patents for their NCEs in Eurasia & Canada. Suven Life Sciences Ltd (Suven) announced on Monday that the grant of three (3) product patents, two (2) from Eurasia (016594&017007) and one (1) from Canada (2683124) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2027. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of impairment cognitive associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of ten (10) granted product patents from Canada & twelve (12) granted product patents from Eurasia, These granted patents are exclusive Intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-l or Phase-II. ‘We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.